Technology is used to grow a patient’s own adult stem cells and will be used by NeoStem in orthopedic conditions.

NeoStem obtained an exclusive royalty-bearing license for Asia to use Regenerative Sciences process that rapidly grows a patient’s own adult stem cells to treat a variety of musculoskeletal diseases. NeoStem will use the Regenexx technology to develop treatments for chronic orthopedic conditions.


NeoStem provides adult stem cell collection and banking to the general population and recently acquired licenses to use stem cells to treat chronic wounds and for cosmetic facial rejuvenation.ADNFCR-2184-ID-19162590-ADNFCR “The minimally invasive Regenexx procedure complements NeoStem’s established in-office stem cell collection procedures and expands our expertise into a new area,” says Robin Smith, M.D. and CEO of NeoStem, “Restoring joints, bone, muscle, and cartilage and combating orthopedic diseases complements our growth in the anti-aging and regenerative medicine arena.”


Regenerative’s founder and CEO, Christopher Centeno, M.D., will serve as a consultant to NeoStem in the area of stem cell therapy in orthopedics and will train NeoStem personnel in mesenchymal stem cell isolation, preparation, and transplantation methods.

Previous articleGE Healthcare to Provide Cytori’s Adipose-Derived Stem Cell Technology in North America
Next articleNovImmune Secures Over $56M to Buy Back Two mAbs from Merck Serono